Association of haptoglobin phenotypes with ceruloplasmin ferroxidase activity in β-thalassemia major

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 975-979

  Awadallah, Samir M ^a   Nimer, Nisreen A ^b   Atoum, Manar F ^b   Saleh, Suleiman A ^b  

^a UNIVERSITY OF SHARJAH   (United Arab Emirates)

^b HASHEMITE UNIVERSITY   (Jordan)

Author keywords

Ceruloplasmin; Ferroxidase; Haptoglobin; Iron overload; Thalassemia

Indexed keywords

C REACTIVE PROTEIN; CERULOPLASMIN; FERRITIN; HAPTOGLOBIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CHILD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; HUMAN; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON OVERLOAD; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PHENOTYPE; PHENOTYPIC VARIATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCHOOL CHILD; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CASE-CONTROL STUDIES; CERULOPLASMIN; CHILD; FEMALE; HAPTOGLOBINS; HUMANS; IRON OVERLOAD; MALE; PHENOTYPE; YOUNG ADULT;

EID: 79955048479     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.02.003     Document Type: Article

References (36)

1. Hershko C., Graham G., Bates G.W., Rachmilewitz E.A. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978, 40:255-263.
2. Cabantchik Z.I., Breuer W., Zanninelli G., Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005, 18:277-287.
3. Cighetti G., Duca L., Bortone L., et al. Oxidative status and malondialdehyde in beta-thalassaemia patients. Eur J Clin Investig 2002, 32(suppl 1):55-60.
4. De Luca C., Filosa A., Grandinetti M., Maggio F., Lamba M., Passi S. Blood antioxidant status and urinary levels of catecholamine metabolites in beta thalassemia. Free Radic Res 1999, 30:453-462.
5. Hershko C., Weatherall D.J. Iron-chelating therapy. Crit Rev Clin Lab Sci 1988, 26:303-345.
6. Koren A., Fink D., Admoni O., Tennenbaum-Rakover Y., Levin C. Non-transferrin bound labile plasma iron and iron overload in Sickle Cell Disease: a comparative study between Sickle Cell Disease and b thalassemic patients. Eur J Haematol 2010, 84:72-78.
7. Chakraborty D., Bhattacharyya M. Antioxidant defense status of red blood cells of patients with b-thalassemia and Ebeta-thalassemia. Clin Chim Acta 2001, 305:123-129.
8. Kassab-Chekir A., Laradi S., Ferchichi S., et al. Oxidant, antioxidant status and metabolic data in patients with beta thalassemia. Clin Chim Acta 2003, 338:79-86.
9. Walter P.B., Fung E.B., Killilea D.W., et al. Oxidative stress and inflammation in iron-overloaded patients with b-thalassaemia or sickle cell disease. Br J Haematol 2006, 135:254-263.
10. Livrea M.A., Tesoriere L., Pintaudi A.M., et al. Oxidative stress and antioxidant status in beta-thalassemia major: Iron overload and depletion of lipid-soluble antioxidants. Blood 1996, 88:3608-3614.
11. Floris G., Medda R., Padiglia A., Musci G. The physiopathological significance of caeruloplasmin. Biochem Pharmacol 2000, 60:1735-1741.
12. Samokyszyn V.M., Miller D., Reif D., Aust S. Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem 1989, 264:21-26.
13. Gutteridge J.M. Antioxidant properties of caeruloplasmin towards iron- and copper-dependent oxygen radical formation. FEBS Lett 1983, 157:37-40.
14. Roeser H.P., Lee G.R., Nacht S., Cartwright G.E. The role of ceruloplasmin in iron metabolism. J Clin Invest 1970, 49:2408-2417.
15. Young S.P., Fahmy M., Golding S. Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells. FEBS Lett 1997, 411:93-96.
16. Goldstein I.M., Kaplan H.B., Edelson H.S., Ceruloplasmin Weissmann G. A scavenger of superoxide anion radicals. J Biol Chem 1979, 254:4040-4045.
17. Attieh Z.K., Mukhopadhyay C.K., Seshadri V., Tripoulas N.A., Fox P.L. Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem 1999, 274:1116-1123.
18. Harris Z.L., Klomp L.W., Gitlin J.D. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998, 67(suppl):972S-977S.
19. Miyajima H., Takahashi Y., Masahiro S., Kaneko E., Gitlin J.D. Increased plasma lipid peroxidation in patients with aceruloplasminemia. Free Radic Biol Med 1996, 20:757-760.
20. Cairo G., Conte D., Bianchi L., Fraquelli M., Recalcati S. Reduced serum ceruloplasmin levels in hereditary haemochromatosis. Br J Haematol 2001, 114:226-229.
21. Yoshida K., Kaneko K., Miyajima H., et al. Increased lipid peroxidation in the brains of aceruloplasminemia patients. J Neurol Sci 2000, 175:91-95.
22. Harris Z.L., Durley A.P., Man T.K., Gitlin J.D. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proc Natl Acad Sci USA 1999, 96:10812-10817.
23. Sarkar J., Seshadri V., Tripoulas N.A., Ketterer M.E., Fox P.L. Role of ceruloplasmin in macrophage iron efflux during hypoxia. J Biol Chem 2003, 278:44018-44024.
24. Langlois M.R., Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996, 42:1589-1600.
25. Van Vlierberghe H., Langlois M., Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin Chim Acta 2004, 345:35-42.
26. Okazaki T., Yangisawa Y., Nagai T. Analysis of the affinity of each haptoglobin polymer for hemoglobin by two-dimensional affinity chromatography electrophoresis. Clin Chim Acta 1997, 258:137-144.
27. Delanghe J.R., Allcock K., Langlois M.R., Claeys L., De Buyzere M.L. Fast determination of hemoglobin-binding capacity using high pressure gel permeation chromatography. Clin Chim Acta 2000, 291:43-51.
28. Langlois M.R., Martin M.-E., Boelaert J.R., et al. The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin Chem 2000, 46:1619-1625.
29. Beutler E., Gelbart T., Lee P. Haptoglobin polymorphism and iron homeostasis. Clin Chem 2002, 48:2232-2235.
30. Kristiansen M., Graversen J.H., Jacobsen C., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
31. Schosinsky H., Lehmann H.P., Beeler M.F. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 1974, 20:1556-1563.
32. Hamad H., Awadallah S. Age group-associated variations in the pattern of Hp type distribution in Jordanians. Clin Chim Acta 2000, 300:75-81.
33. Kohgo Y., Ikuta K., Ohtake T., Torimoto Y., Kato J. Body iron metabolism and pathophysiology of iron overload. Int J Hematol 2008, 88:7-15.
34. Esposito B.P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z.I. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003, 102:2670-2677.
35. Pedersen J.Z., Franck C. Increased serum levels of ceruloplasmin in severe chronic airflow obstruction. Eur J Respir Dis 1987, 70:140-144.
36. Van Vlierberghe H., Langlois M., Delanghe J., et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001, 35:707-711.